Amgen Inc. with ticker code (AMGN) have now 23 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $380.00 and $170.00 calculating the mean target price we have $320.24. Now with the previous closing price of $332.47 this indicates there is a potential downside of -3.7%. There is a 50 day moving average of $315.92 while the 200 day moving average is $291.59. The market cap for the company is 179.99B. The current share price for the company is: $335.53 USD
The potential market cap would be $173,369,053,696 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 47.86, revenue per share of $55.15 and a 4.88% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
